Form 4: Rhythm Pharmaceuticals Executive Alastair Garfield Reports Stock Option and Restricted Stock Unit Grants

Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• Alastair Garfield, the Chief Scientific Officer of Rhythm Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On July 8, 2024, Garfield acquired 53,333 stock options with an exercise price of $43.76.
• These options vest over four years, with 6.25% vesting every three months starting July 1, 2024, and becoming fully vested by July 1, 2028.
• Garfield also acquired 17,778 restricted stock units, each representing a contingent right to receive one share of Rhythm Pharmaceuticals common stock.
• These restricted stock units vest in four equal installments of 25% on each of the first four anniversaries of July 1, 2024.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating a stable and incentivized management structure. This is generally viewed positively.

Positives

• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the Chief Scientific Officer.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules, such as the four-year vesting described, are typical to ensure long-term alignment with company goals.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize similar equity-based compensation strategies for their executives.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment to leadership.

Key Dates